This operation aims to accelerate the commercialization of the medical robot Epione, designed for minimally invasive treatment of abdominal and lung cancer.
After selling its first robot in the United States in December 2023 and the acquisition of Epione® by the Paoli-Calmettes Institute in Marseille in March 2024, the financing will accelerate the commercial development of the company. This is the second loan granted by the EIB to Quantum Surgical, following an initial financing in 2021 for the commercial launch of Epione.
Epione® is a technology combining robotics and AI that enables interventional radiologists to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment where one or more needles are inserted through the skin to destroy the tumor.
Ad Statistics
Times Displayed: 174428
Times Visited: 3180 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is available in France, at the Gustave Roussy Cancer Center in Villejuif, at the Hospices Civils de Lyon as well as at the Paoli-Calmettes Institute in Marseille, and in Miami, United States.
More than 4 million new cases of abdominal and lung cancers are diagnosed each year worldwide. Several hundred patients have already been treated worldwide using Quantum Surgical's medical platform.
"At Quantum Surgical, our goal is to provide patients with innovative and effective treatment on a global scale. We are delighted to receive support once again from the EIB. This demonstrates that our technology is destined for global adoption to revolutionize cancer treatment," says Bertin Nahum, CEO and co-founder of Quantum Surgical.
"Already a partner of Quantum Surgical, the EIB is pleased to once again support the development of a surgical robot that has proven its worth in the medical field. This €30 million financing demonstrates Europe's commitment to supporting innovation and promising technologies in the healthcare sector, essential for improving the lives and well-being of patients on a much larger scale," stated Ambroise Fayolle, Vice President of the European Investment Bank.
About Quantum Surgical
Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Combining robotics and AI, its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.
